Cardiovascular research continues to be a major focus at Saint Luke’s Health System. The program currently encompasses research programs in each of the major clinical areas, including:

  • Interventional cardiology
  • Cardiac surgery
  • Heart failure
  • Cardiac transplantation
  • Cardiac electrophysiology
  • Cardiac imaging
  • Preventive cardiology/lipid
  • Diabetes management
  • Adult congenital heart disease

Hundreds of patients enroll in these programs annually for a broad range of randomized trials and registry-based research studies, making the programs essential to the mission of Saint Luke’s Mid America Heart Institute. Research allows the Heart Institute to remain on the leading edge of cardiovascular care. In addition to these clinical research programs, many Heart Institute cardiologists participate in research through the Ben D. McCallister Clinical Scholars Program, which provides funding and support for investigator-initiated studies.

In addition to supporting clinical research, the cardiovascular research program encompasses centers of excellence and core laboratories in cardiovascular outcomes research, health economics and technology assessment, intravascular imaging, and noninvasive imaging. These centers of excellence currently serve as core laboratories for a wide range of studies that often involve collaboration with other leading cardiovascular centers and researchers from around the world. The Heart Institute continues to serve as one of the four Analytic Centers, along with Duke, Harvard, and Yale, for the American College of Cardiology’s National Cardiovascular Data Registry.

Contact Us

For more information, call 816-932-4581.

News

New Research Finds Promising Therapy to Prevent Alzheimer’s Disease
A new study co-authored by Saint Luke’s cardiologist James O’Keefe, MD suggests that therapies to block a hormone called TNF can greatly reduce the risk of developing Alzheimer’s disease.
U.S. News & World Report: High ozone levels up cardiac arrest risk: study
High levels of ozone air pollution could increase the risk of cardiac arrest, according to a new study. Dr. Ali Malik explains why the findings may have important public health implications.
U.S. News & World Report: MRIs might be safe for patients with implanted heart devices
Dr. Sanjaya Gupta explains the findings of the recent study and what this means for patients moving forward.
TCTMD: EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes
In patients remotely monitored with an implanted device, the differences appeared to emerge early and widen with time.
Healio: Two studies provide further positive outcomes for empagliflozin in HF
Dr. Mikhail Kosiborod explains the results of the EMBRACE-HF study looking at the impact of empagliflozin in patients with HF and higher diastolic pulmonary artery pressure.
Healio: No difference in sustained health status improvements in TAVR vs. surgical AVR
Patients who had TAVR had similar health status after five years with those who had surgical AVR, according to a new study by Dr. Suzanne Arnold.
Healio: DARE-19: Dapagliflozin could target key mechanisms activated in COVID-19
As the entire world comes together to attempt to find a vaccine and treatments for this global pandemic, it is exciting that an international trial of this nature was created and is being led by doctors and researchers here in
blood glucose testing paper with a stethoscope and a heart shape bowl with healthy foods to fight diabetes
Saint Luke’s Mid America Heart Institute Announces Launch of National Cardiometabolic Center Alliance
Alliance to establish Cardiometabolic Centers of Excellence across the nation.
KMBC: Worldwide clinical drug trial for COVID-19 led by a doctor at Saint Luke's
KMBC: Worldwide clinical drug trial for COVID-19 led by a doctor at Saint Luke's
As the entire world comes together to attempt to find a vaccine and treatments for this global pandemic, it is exciting that an international trial of this nature was created and is being led by doctors and researchers here in Kansas City.
KCTV: Saint Luke’s Launches Global Clinical Trial to Investigate Potential COVID-19 Treatment
KCTV: Saint Luke’s Launches Global Clinical Trial to Investigate Potential COVID-19 Treatment
As the entire world comes together to attempt to find a vaccine and treatments for this global pandemic, it is exciting that an international trial of this nature was created and is being led by doctors and researchers here in Kansas City.
Blue sphere COVID-19 viruses
Kansas City Business Journal: Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious COVID-19 complications
Saint Luke's Mid America Heart Institute and drug company AstraZeneca PLC are conducting a clinical trial to see if a drug now used to treat diabetes could help prevent deadly complications in COVID-19 patients.
COVID-19 testing tube with graph transposed overtop
Saint Luke’s Mid America Heart Institute and AstraZeneca initiate Phase III DARE-19 trial in COVID-19 patients
The trial will assess the potential of dapagliflozin in reducing the risk of serious complications and organ failure.
ISCHEMIA
TCTMD: ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up
The ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial focused on evaluating survival and benefits to the patients quality of life.
stethoscope laying on of of data sheets with computer and physician hands on keyboard with research and data points
NIH-funded studies show stents and surgery no better than medication, lifestyle changes at reducing cardiac events
Saint Luke's Director of Health Outcomes and Research at Saint Luke's Mid America Heart Institute helps in NIH-funded studies that find stents, surgery provide higher quality of life for those with chest pain.
Patient-Centered Outcomes Research Institute (PCORI) logo
Kansas City Researcher Earns National PCORI Engagement Award
Funds will support an easy-step program to encourage at-risk communities to take charge of vascular health, starting with a first public event on Nov. 13
Hand pointing to a heart with EKG heart rhythm on it.
Cardiovascular Business: Cardiac amyloidosis increasingly common in US
Brett Sperry, MD, Ibrahim Saeed, MD, John Spertus, MD, and Shahzad Raza, MD, worked on a recent study published in the American Journal of Cardiology on the rising trend of amyloidosis cases.
hand holding heart-shaped pill
TCTMD: DEFINE-HF: Dapagliflozin Improves Function and Quality of Life, but Not Biomarkers, in HFrEF
A new study championed by Saint Luke's, called DEFINE-HF, was recently presented at the Heart Failure Society of America annual meeting. tctMD breaks down this groundbreaking study of the new treatment option with study chair Mikhail Kosiborod, MD.